Company / Operating Income per Share
MoonLake Immunotherapeutics Operating Income per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$3.80
FY2025
5-year range
-$6.83 / -$1.10
FY2021-FY2025
Trend
-66.9%
vs FY2024
Sector context
#157 of 201
Health Care
What the data says
MoonLake Immunotherapeutics's operating income per share of $-3.80 is lower than 78% of companies in the Health Care sector (FY2025). Declined from $-1.10 to $-3.80 over the past 2 years.
Based on SEC 10-K filings.
-3.80 in FY2025.
Declined from $-1.10 to $-3.80 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 201This company -$3.80 Sector average -$28.56
▼
+86.7% above sector average
Key checks
Key Insights
- In FY2025, operating income per share decreased 66.9% year-over-year.
- Ranks #157 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2020.
- Lowest operating income per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.80 | -66.9% |
| FY2024 | -$2.28 | -106.6% |
| FY2023 | -$1.10 | +50.3% |
| FY2022 | -$2.22 | +67.6% |
| FY2021 | -$6.83 | -40167.6% |
| FY2020 | -$0.02 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026